In addition to early detection, novel biomarkers such as NGAL, KIM-1, and [TIMP-2]·[IGFBP7] have demonstrated value in stratifying AKI severity, identifying subclinical kidney injury, and guiding risk-based therapeutic strategies [5]. This evidence concerns the gene HAVCR1 and acute kidney injury.